US 3,962,266 AGrant
Novel Substituted Benzopyranopyridine
Issue Date:1976-06-08
•2 Claims
Abstract
Disclosed is a novel substituted benzopyranopyridine which is active as a bronchodilator agent.
Metadata
Assignee
- Warner-Lambert Company
Inventors
- Richard E. Brown
- Chester Puchalski
- John Shavel, Jr.
Application Information
Application Number:US 5736684
Filing Date:1975-05-01
Priority Date:1971-03-09
Art Unit:125
Classifications
IPC:
C07D51900
Field of Search:
260295 T
Patent Drawings
This patent does not have any drawings.
Description
This invention relates to novel substituted benzopyranopyridines of the formula I: ##SPC1##
In the above formula, R.sub.1 and R.sub.2 may be hydrogen, hydroxy, lower alkoxy or lower alkyl of 1 to 6 carbon atoms or may be taken together to form a methylenedioxy group.
The compounds of this invention are prepared by reacting a substituted benzopyranopyridine of structure II with a suitable alkylating agent of structure III. In structure II, R.sub.1 and R.sub.2 are as defined for formula I. In structure III, hal. refers to halogen and may be chlorine, bromine or iodine. ##SPC2##
The starting materials according to structure II are described in our application Ser. No. 534,502. The alkylation reactions are carried out in a suitable solvent in the presence of a base to serve as proton acceptor. Among the solvents which may be used are alcohols of 1 to 6 carbon atoms such as methanol, ethanol or amyl alcohol; polar aprotic solvents as dimethylformamide, dimethylsulfoxide and the like, tetrahydrofuran and dioxane. Suitable bases are potassium carbonate, sodium acetate or triethylamine and the like.
The alkylating agents according to structure III are known compounds and were prepared according to the procedure described (P. Chabrier, et al., Bull. Soc. Chim. Fi., 1957, 1365).
The following examples are given in order to further illustrate the invention: ##SPC3##
1,2,3,4-Tetrahydro-8,9-dimethoxy-3-[2-(1,2,3,6-tetrahydro-1-pyrioyl) ethyl]-5H-[1]benzopyrano[3,4-c]pyridin-5-one dihydrochloride. A mixture of 0.04m of 1,2,3,4-tetrahydro-8,9-dimethoxy-5H-[1]benzopyrano [3,4-c]pyridin-5-one, 0.047m of N-(2-chloroethyl)1,2,3,6-tetrahydropyridine HCl and 0.05m of triethylamine was refluxed for 6 hours, filtered while hot and treated immediately with excess HCl gas. The crude product was crystallized from methanol to give 7.8g of material, m.p. 236.degree.-9.degree. C.
Anal. Calcd. for C.sub.21 H.sub.26 N.sub.2 O.sub.4 2HCl: C, 56.89; H, 6.37; N, 6.32; Cl, 15.99. Found: C, 56.65; H, 6.30; N, 6.17; Cl, 15.83.
Twelve animals were tested for bronchodilation according to Example II. Histamine was used as the spasmogen in all instances. Two separate tests were run with the results given in Table I:
The protection which the compound of Example 1 has can be easily seen from this table.
The compound of Example 1 is active as a bronchodilator for all spasmogens listed in Example 2, and protects the guinea pig against bronchospasm for a duration up to four hours at an oral dose of 10 mg/kg. Thus, it is more effective against bronchospasm than aminophylline, a commercial product used in the treatment of bronchial asthma and pulmonary edema, which protects the guinea pig against identical bronchospasm for less than two hours at a dose of 100 mg/kg. In addition, the compound of Example 1 reverses pilocarpine or histamine bronchoconstriction in the dog for a duration of up to 1 hour at an oral dose of 10 mg/kg. The bronchodilator activity exhibited by the N-substituted benzopyrano[3,4-c] pyridine described in this invention is the result of a direct smooth muscle relaxant effect on the bronchial tree as shown by in vitro experiments on guinea pig trachea. In these experiments, the N-substituted benzopyrano [3,4-c]pyridine is approximately 75 times more active than aminophylline in relaxing tracheal smooth muscle.
The compounds of this invention are useful for the treatment of bronchial asthma. Generally speaking, a dose of about 500 mg to 1000 mg several times daily is recommended for mammals weighing about 70 kilograms. The compounds can be administered orally or by parenteral administration.
In order to use these compounds they are formulated with pharmaceutically acceptable excipients such as lactose, starch, powdered sugar and the dosage forms can be tablets, capsules and the like. The dosage regimen can be varied according to the condition being treated by methods well known to the healing arts.
Claims
We claim:
1. A substituted benzopyranopyridine of the formula; ##SPC4## wherein R.sub.1 and R.sub.2 may be hydrogen, hydroxy, lower alkoxy, or lower alkyl of 1 to 6 carbon atoms or taken together from a methylenedioxy group.
2. The compound according to claim 1 which is 1,2,3,4-tetrahydro-8,9-dimethoxy-3-[2-(1,2,3,6-tetrahydro-1-pyridyl)ethyl] -5H-[1]benzopyrano[3,4-c] pyridin-5-one.
Patent Citations (5)
| Patent | Date | Inventor | Cited By |
|---|---|---|---|
| US3396165 | 1968-08-01 | Bolger | |
| US3429889 | 1969-02-01 | Shulgin | |
| US3514464 | 1970-05-01 | Pars et al. | |
| US3689497 | 1972-09-01 | Brown et al. | |
| US3803153 | 1974-04-01 | Villani |